Oncology · Urothelial CarcinomaTrial Updateclinicalmid-term

Tyra Biosciences initiates Phase 2A/B trial of Dabogratinib for Low Grade Upper Tract Urothelial Carcinoma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Tyra Biosciences2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 6:04:37 AM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the Phase 2A/B trial for Dabogratinib by Tyra Biosciences is significant as it targets a niche indication in oncology, potentially filling an unmet need in low-grade upper tract urothelial carcinoma. Positive trial outcomes could strengthen Tyra's competitive position and expand its oncology portfolio. Regulatory context from MHRA (MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer) supports the near-term read. Assessment grounded in 4 ranked evidence items (2 high-relevance).

Strategic Assessment

Success in this trial could enhance Tyra's portfolio and market position in oncology, particularly in niche indications. The strongest clinical anchor is Unilateral Compound Training Reduces Lower-Limb Strength Asymmetry and Enhances Athletic Performance in Female Handball Players: A Randomized Controlled Trial (ClinicalTrials.gov), mechanism alignment (io ). In bladder cancer, 1 regulatory and 1 competitive items passed relevance filtering for Tyra Biosciences.

Competitive Pressure

The most relevant competitive pressure comes from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) (Merck) — sponsor/company relevance (merck). This trial positions Tyra Biosciences in the competitive landscape of treatments for urothelial carcinoma, potentially addressing an unmet need in low-grade cases.

Regulatory Outlook

Regulatory risk is concentrated around MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer (MHRA). Sub-indication match (bladder cancer). The trial's results will be critical for future regulatory submissions and could influence labeling and approval pathways for treatments in this indication.

Key Risks

Elevated medium regulatory exposure for Tyra Biosciences could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, Dabogratinib could capture market share in a specialized segment, enhancing Tyra's revenue potential and positioning against competitors in the urothelial carcinoma space.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
Success in this trial could enhance Tyra's portfolio and market position in oncology, particularly in niche indications.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Sub-indication match (bladder cancer)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (indication); Broad oncology match without sub-indication specificity
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (indication); Broad oncology match without sub-indication specificity
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Unilateral Compound Training Reduces Lower-Limb Strength Asymmetry and Enhances Athletic Performance in Female Handball Players: A Randomized Controlled Trial
ClinicalTrials.govmedium relevance
Mechanism alignment (IO )
FDA document
View source
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source

Leverage of quick-soluble gelatin microparticles in transarterial chemoembolization of canine urothelial carcinomas.
PubMedhigh relevance
Sub-indication match (bladder cancer)
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
An extract from whole Coffea arabica coffee cherry improves time trial performance, but not muscle glycogen resynthesis, in trained cyclists.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Tyra Biosciences
Dabogratinib

Commercial impact

medium

If successful, Dabogratinib could capture market share in a specialized segment, enhancing Tyra's revenue potential and positioning against competitors in the urothelial carcinoma space.

Regulatory impact